SWTX
Income statement / Annual
Last year (2023), SpringWorks Therapeutics, Inc.'s total revenue was $5.45 M,
a decrease of 11.39% from the previous year.
In 2023, SpringWorks Therapeutics, Inc.'s net income was -$325.10 M.
See SpringWorks Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$5.45 M
|
$6.15 M
|
$0.00
|
$35.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$422,000.00 |
$1.90 M |
$490,000.00 |
$349,000.00 |
$192,000.00 |
$17,328.00 |
$3,182.00 |
| Gross Profit |
$5.03 M |
$4.25 M |
-$490,000.00 |
$34.65 M |
-$192,000.00 |
-$17,328.00 |
-$3,182.00 |
| Gross Profit Ratio |
0.92 |
0.69 |
0 |
0.99 |
0 |
0 |
0 |
| Research and Development
Expenses |
$150.49 M
|
$146.12 M
|
$101.68 M
|
$51.86 M
|
$42.55 M
|
$9.90 M
|
$2.80 M
|
| General & Administrative
Expenses |
$197.55 M
|
$134.55 M
|
$71.79 M
|
$29.47 M
|
$16.69 M
|
$8.59 M
|
$5.58 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.73 M
|
| Selling, General &
Administrative Expenses |
$197.55 M
|
$134.55 M
|
$71.79 M
|
$29.47 M
|
$16.69 M
|
$8.59 M
|
$1.86 M
|
| Other Expenses |
$0.00 |
-$138,000.00 |
-$152,000.00 |
$25,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$348.04 M |
$280.67 M |
$173.47 M |
$81.32 M |
$59.24 M |
$18.49 M |
$4.66 M |
| Cost And Expenses |
$348.46 M |
$280.67 M |
$173.47 M |
$81.32 M |
$59.24 M |
$18.49 M |
$4.66 M |
| Interest Income |
$22.95 M |
$6.29 M |
$698,000.00 |
$1.33 M |
$3.55 M |
$678,000.00 |
$63,000.00 |
| Interest Expense |
$0.00 |
-$765,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.67 M
|
$1.90 M
|
$490,000.00
|
$349,000.00
|
$192,000.00
|
$17,328.00
|
$3,182.00
|
| EBITDA |
-$341.35 M
|
-$280.67 M
|
-$172.98 M
|
-$45.98 M
|
-$59.05 M
|
-$18.47 M
|
-$4.66 M
|
| EBITDA Ratio |
-62.67 |
-45.66 |
0 |
-1.31 |
0 |
0 |
0 |
| Operating Income Ratio
|
-62.97
|
-45.66
|
0
|
-1.32
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$5.04 M
|
$3.26 M
|
-$442,000.00
|
$750,000.00
|
$933,000.00
|
$678,000.00
|
$21,000.00
|
| Income Before Tax |
-$325.10 M |
-$277.42 M |
-$173.91 M |
-$45.57 M |
-$58.31 M |
-$17.81 M |
-$4.64 M |
| Income Before Tax Ratio
|
-59.68
|
-45.13
|
0
|
-1.3
|
0
|
0
|
0
|
| Income Tax Expense |
-$22.95 M |
-$3.26 M |
-$698,000.00 |
-$1.33 M |
-$3.55 M |
$678,000.00 |
-$2.00 |
| Net Income |
-$325.10 M |
-$274.16 M |
-$173.21 M |
-$44.24 M |
-$54.76 M |
-$17.81 M |
-$4.64 M |
| Net Income Ratio |
-59.68 |
-44.6 |
0 |
-1.26 |
0 |
0 |
0 |
| EPS |
-5.15 |
-5.14 |
-3.57 |
-1.02 |
-1.27 |
-0.8 |
-0.11 |
| EPS Diluted |
-5.15 |
-5.14 |
-3.57 |
-1.02 |
-1.27 |
-0.8 |
-0.11 |
| Weighted Average Shares
Out |
$63.12 M
|
$53.29 M
|
$48.50 M
|
$43.30 M
|
$43.01 M
|
$22.20 M
|
$43.23 M
|
| Weighted Average Shares
Out Diluted |
$63.12 M
|
$53.29 M
|
$48.50 M
|
$43.30 M
|
$43.01 M
|
$22.20 M
|
$43.23 M
|
| Link |
|
|
|
|
|
|
|
